Zenith Epigenetics Ltd. is a clinical stage biotechnology company developing best in class bromodomain (BET) inhibitors for the treatment of cancer and other disorders with significant unmet medical need. Our cutting edge epigenetic platform of innovative biology and chemistry has generated differentiated, potent and selective BET inhibitors. Our goal is to be a leading epigenetic company translating bromodomain biology into impactful therapies. Our lead product, a pan selective BET inhibitor, is in clinical development for treatment of solid tumors, including prostate cancer. Our strong management team and organization allow us to efficiently and rapidly explore and progress molecules from discovery to clinical development. Our research team, based in Calgary, Alberta, is well-positioned to take advantage of its broad and longstanding experience in epigenetics to become a leader in the discovery of selective BET inhibitors in both oncology and other indications. The development activities are led by our San Francisco based team, where a strong emphasis on translational medicine to drive patient pre-selection combined with a proven track record in drug development, will allow us to excel in the field of epigenetics. Zenith Epigenetics is a wholly-owned subsidiary of Zenith Capital Corp.